Skip to main content

Table 1 Baseline characteristics of the study population

From: Predictive value of CHA2DS2-VASc score combined with hs-CRP for new-onset atrial fibrillation in elderly patients with acute myocardial infarction

Variables NOAF (n = 30) Without NOAF (n = 281) P value
Age, years 82.43 ± 9.21 73.37 ± 10.31 < 0.001
Male, n (%) 23 (76.67) 229 (81.49) 0.322
STEMI, n (%) 19 (63.33) 175 (62.78) 0.925
HT, n (%) 18 (60) 156 (55.52) 0.761
DM, n (%) 9 (30) 95 (33.81) 0.546
History of MI, n (%) 8 (26.67) 50 (17.79) 0.179
History of PCI, n (%) 5 (16.67) 39 (13.88) 0.159
History of CABG, n (%) 2 (6.67) 7 (2.49) 0.192
History of CHF, n (%) 2 (6.67) 29 (10.32) 0.564
History of stroke, n (%) 6 (20) 38 (13.52) 0.218
Current smoker, n (%) 16 (53.33) 166 (59.07) 0.45
BMI, kg/m2 24.33 ± 2.39 26.19 ± 3.07 0.061
SBP, mmHg 122.37 ± 22.82 126.49 ± 19.83 0.172
DBP, mmHg 66.37 ± 12.41 65.49 ± 13.29 0.223
HR at admission, bpm 74 ± 13.6 78.56 ± 12.49 0.074
IRA    
 RCA, n (%) 8 (26.67) 92 (32.74) 0.304
 LAD, n (%) 13 (43.33) 123 (43.77) 0.932
 LCX, n (%) 7 (23.33) 57 (20.28) 0.21
Killip class    
 I, n (%) 7 (23.33) 118 (41.99) 0.003
 II, n (%) 13 (43.33) 132 (46.98) 0.317
 III, n (%) 8 (26.67) 22 (7.83) 0.001
 IV, n (%) 2 (6.67) 9 (3.2) 0.135
WBC, 109/L 9.88 ± 2.83 10.34 ± 3.42 0.543
Hb, g/L 135.78 ± 20.36 139.74 ± 19.18 0.263
PLT, 109/L 210.2 ± 58.74 223.17 ± 65.39 0.053
HbAlc, % 6.1 (5.85–7.4) 6.3 (5.6–7.2) 0.684
ESR, mm/h 11.3 (5.55–24.78) 8.1 (4.08–15.1) 0.084
Hs-CRP, mg/L 28.03 (2.64–91.38) 5.2 (2.21–19.04) 0.003
D-dimer, mg/L FEU 0.35 (0.22–0.89) 0.29 (0.2–0.61) 0.144
CK-MB, ng/ml 18.54 (9.6–100.44) 35.29 (6.2–133.41) 0.677
CTnI, ng/ml 17.22 (7.11–106.3) 30.01 (6.32–109.71) 0.747
TC, mmol/L 4.3 ± 1.02 4.49 ± 1.11 0.169
TG, mmol/L 1.37 (0.92–1.77) 1.41 (1.01–2.1) 0.171
LDL-C, mmol/L 2.67 ± 1.18 3.03 ± 1.16 0.079
HDL-C, mmol/L 0.97 ± 0.24 0.96 ± 0.25 0.994
LP(a), mg/dl 16.4 (8.51–23.6) 14.04 (8.43–29.82) 0.961
BNP, pg/ml 384 (184–886.41) 151.3 (72.56–278.53) < 0.001
SCR, µmol/L 68.1 (56.1–95.47) 67.42 (58.77–81.39) 0.948
eGFR, ml/min/1.73 m2 99.37 ± 32.51 107.24 ± 30.57 0.125
SUA, umol/L 397.81 ± 141.27 384.19 ± 103.99 0.211
LVEF, % 53.6 (40.72–63.19) 61.4 (48.79–66.3) 0.023
LVESd, mm 34 (30.1–38.1) 32 (28–39) 0.109
LVEDd, mm 48.4 (44.91–54.2) 48 (44–52) 0.362
LAD,mm 38.1 (34.7–42.59) 35.2 (33.2–38.4) 0.031
Medications    
 ACEI/ARB, n (%) 5 (16.67) 107 (38.08) 0.046
 Beta blocker, n (%) 14 (46.67) 186 (66.19) 0.069
 Statin, n (%) 28 (93.33) 272 (96.78) 0.367
IABP, n (%) 5 (16.67) 28 (9.96) 0.055
CHADS2 score 2 (1–3) 1 (1–2) 0.019
CHA2DS2-VASc score 4 (3–5) 3 (2–4) 0.001
In-hospital mortality, n (%) 3 (10) 3 (1.06)  < 0.001
  1. Data are number (%), mean (SD), or median (IQR)
  2. NOAF, new-onset atrial fibrillation; STEMI, ST-segment elevation myocardial infarction; HT, hypertension; DM, diabetes mellitus; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CHF, chronic heart failure; BMI, body mass Index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; IRA, infarct related artery; RCA, right coronary artery; LAD, left anterior descending artery; LCX, left circumflex coronary artery; WBC, white blood cell; Hb, haemoglobin; PLT, platelet; HbAlc, glycosylated hemoglobin; ESR, erythrocyte sedimentation rate; Hs-CRP, high sensitive c-reactive protein; HCY, homocysteine; CK-MB, creatine kinase MB; CTnI, cardiac troponin I; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LP(a), Lipoprotein (a); BNP, B-type natriuretic peptide; SCR, serum creatinine; eGFR, estimated glomerular filtration rate; SUA, serum uric acid; LVEF, left ventricular ejection fraction; LVESd, left ventricular end-systolic diameter; LVEDd, left ventricular end-diastolic diameter; LAD, left atrium diameter; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; IABP, intra-aortic ballon pump